These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11440162)

  • 1. Molecular docking-based test for affinities of two ligands toward vasopressin and oxytocin receptors.
    Slusarz R; Kaźmierkiewicz R; Giełdoń A; Lammek B; Ciarkowski J
    Acta Biochim Pol; 2001; 48(1):131-5. PubMed ID: 11440162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
    Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional architecture of vasopressin/oxytocin receptors.
    Hibert M; Hoflack J; Trumpp-Kallmeyer S; Mouillac B; Chini B; Mahé E; Cotte N; Jard S; Manning M; Barberis C
    J Recept Signal Transduct Res; 1999; 19(1-4):589-96. PubMed ID: 10071787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
    Slusarz MJ; Slusarz R; Ciarkowski J
    Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes.
    Cottet M; Albizu L; Perkovska S; Jean-Alphonse F; Rahmeh R; Orcel H; Méjean C; Granier S; Mendre C; Mouillac B; Durroux T
    Curr Opin Pharmacol; 2010 Feb; 10(1):59-66. PubMed ID: 19896898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
    Slusarz MJ; Sikorska E; Slusarz R; Ciarkowski J
    J Med Chem; 2006 Apr; 49(8):2463-9. PubMed ID: 16610789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics simulation of human neurohypophyseal hormone receptors complexed with oxytocin-modeling of an activated state.
    Slusarz MJ; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):171-9. PubMed ID: 16114099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling of the oxytocin receptor/bioligand interactions.
    Politowska E; Czaplewski C; Ciarkowski J
    Acta Biochim Pol; 1999; 46(3):581-90. PubMed ID: 10698266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics study of the internal water molecules in vasopressin and oxytocin receptors.
    Slusarz MJ; Slusarz R; Ciarkowski J
    Protein Pept Lett; 2009; 16(4):342-50. PubMed ID: 19356129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking ligands to vasopressin and oxytocin receptors via genetic algorithm.
    Politowska E; Drabik P; Kazmierkiewicz R; Ciarkowsk J
    J Recept Signal Transduct Res; 2002; 22(1-4):393-409. PubMed ID: 12503629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transmission via G protein-coupled receptors in the light of rhodopsin structure determination.
    Ciarkowski J; Drabik P; Giełdoń A; Kaźmierkiewicz R; Slusarz R
    Acta Biochim Pol; 2001; 48(4):1203-7. PubMed ID: 11995993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.
    Howl J; Wheatley M
    Biochem J; 1996 Jul; 317 ( Pt 2)(Pt 2):577-82. PubMed ID: 8713088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
    Bellenie BR; Barton NP; Emmons AJ; Heer JP; Salvagno C
    Bioorg Med Chem Lett; 2009 Feb; 19(3):990-4. PubMed ID: 19095447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological lineage analysis revealed the binding affinity of broad-spectrum substance P antagonists to receptors for gonadotropin-releasing peptide.
    Arai K; Kashiwazaki A; Fujiwara Y; Tsuchiya H; Sakai N; Shibata K; Koshimizu TA
    Eur J Pharmacol; 2015 Feb; 749():98-106. PubMed ID: 25592317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis of ligand binding and receptor activation in the oxytocin and vasopressin receptor family.
    Chini B; Fanelli F
    Exp Physiol; 2000 Mar; 85 Spec No():59S-66S. PubMed ID: 10795907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor.
    Breton C; Chellil H; Kabbaj-Benmansour M; Carnazzi E; Seyer R; Phalipou S; Morin D; Durroux T; Zingg H; Barberis C; Mouillac B
    J Biol Chem; 2001 Jul; 276(29):26931-41. PubMed ID: 11337500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling of the neurohypophyseal receptor/atosiban complexes.
    Slusarz MJ; Slusarz R; Kaźmierkiewicz R; Trojnar J; Wisniewski K; Ciarkowski J
    Protein Pept Lett; 2003 Jun; 10(3):295-302. PubMed ID: 12871142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of vasopressin and oxytocin receptors with vasopressin analogues substituted in position 2 with 3,3'-diphenylalanine--a molecular docking study.
    Slusarz MJ; Sikorska E; Slusarz R
    J Pept Sci; 2013 Feb; 19(2):118-26. PubMed ID: 23303737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specification of the cholesterol interaction with the oxytocin receptor using a chimeric receptor approach.
    Wiegand V; Gimpl G
    Eur J Pharmacol; 2012 Feb; 676(1-3):12-9. PubMed ID: 22178922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the activation and ligand recognition of the human oxytocin receptor.
    Waltenspühl Y; Ehrenmann J; Vacca S; Thom C; Medalia O; Plückthun A
    Nat Commun; 2022 Jul; 13(1):4153. PubMed ID: 35851571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.